Chimerix Inc. (NASDAQ:CMRX) Insider M Michelle Berrey purchased 14,065 shares of Chimerix stock in a transaction dated Tuesday, May 27th. The shares were purchased at an average price of $14.22 per share, with a total value of $200,004.30. Following the transaction, the insider now directly owns 83,271 shares in the company, valued at approximately $1,184,114. Chimerix Inc. (NASDAQ:CMRX) weekly performance is 8.02%. On last trading day company shares ended up $18.45. Analysts mean target price for the company is $31.67. Chimerix Inc. (NASDAQ:CMRX) distance from 50-day simple moving average (SMA50) is -7.60%.
XenoPort Inc. (NASDAQ:XNPT) Director John Gordon Freund purchased 15,000 shares of the company’s stock on the open market in a transaction dated Friday, May 23rd. The stock was purchased at an average cost of $3.73 per share, for a total transaction of $55,950.00. Following the acquisition, the director now directly owns 8,899 shares in the company, valued at approximately $33,193. XenoPort, Inc. (NASDAQ:XNPT) shares fell -3.34% in last trading session and ended the day on $4.05. XNPT gross Margin is 85.30% and its return on assets is -76.30%.XenoPort, Inc. (NASDAQ:XNPT) quarterly performance is -35.20%.
Cempra Holdings (NASDAQ:CEMP) Director John Johnson bought 10,000 shares of the stock on the open market in a transaction dated Friday, May 23rd. The stock was purchased at an average price of $9.10 per share, for a total transaction of $91,000.00. Following the acquisition, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $91,000. Cempra Inc. (NASDAQ:CEMP) shares moved down -2.07% in last trading session and was closed at $9.46, while trading in range of $9.27 – $9.62. Cempra Inc. (NASDAQ:CEMP) year to date (YTD) performance is -23.65%.
GenVec Inc. (NASDAQ:GNVC) major shareholder Ecor1 Capital, Llc acquired 24,140 shares of GenVec stock in a transaction dated Tuesday, May 27th. The shares were purchased at an average price of $2.24 per share, with a total value of $54,073.60. GenVec Inc. (NASDAQ:GNVC) ended the last trading day at $2.48. Company weekly volatility is calculated as 8.33% and price to cash ratio as 2.80.GenVec Inc. (NASDAQ:GNVC) showed a positive weekly performance of 16.98%.
Idera Pharmaceuticals Inc. (NASDAQ:IDRA)’s Director James A Geraghty purchased 10,000 shares of IDRA in a transaction dated on May 27, 2014. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) shares were bought at an average price of $2.65 for total worth of $26,500.00. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) weekly performance is 13.28%. On last trading day company shares ended up $2.90. Analysts mean target price for the company is $7.00. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) distance from 50-day simple moving average (SMA50) is -14.11%.